Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dexmedetomidine-esketamine combination

Approved

PPeking University First Hospital

Dexmedetomidine-esketamine combination is one of 2 therapeutic programs targeting Older Patients. It is currently in Approved.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Older PatientsCompleted

Older PatientsApproved

Completed

Competition

Competitive Landscape

1 competitor in Older Patients

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Dexmedetomidine-esketamine combination

PPeking University First Hospital

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Older Patients1 trial

Effect of Sedation With Dexmedetomidine-esketamine Combination on Delirium in Postoperative ICU Patients: a Randomized Controlled Pilot Trial

Completed·PPeking University First Hospital·Approved·NCT07151716·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dexmedetomidine-esketamine combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dexmedetomidine-esketamine combination. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Peking University First Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: PPeking University First Hospital

Related News